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Abstract
Impaired protein clearance likely increases the risk of protein accumulation disorders includ-
ing Alzheimer’s disease (AD). Protein degradation through the proteasome pathway
decreases with age and in AD brains, and the Aβ42 peptide has been shown to impair pro-
teasome function in cultured cells and in a cell-free model. Here, Aβ42 was studied in brain
tissue to measure changes in protein clearance pathways and related secondary pathology.
Oligomerized Aβ42 (0.5–1.5 μM) reduced proteasome activity by 62% in hippocampal slice
cultures over a 4-6-day period, corresponding with increased tau phosphorylation and
reduced synaptophysin levels. Interestingly, the decrease in proteasome activity was asso-
ciated with a delayed inverse effect, >2-fold increase, regarding lysosomal cathepsin B
(CatB) activity. The CatB enhancement did not correspond with the Aβ42-mediated phos-
pho-tau alterations since the latter occurred prior to the CatB response. Hippocampal slices
treated with the proteasome inhibitor lactacystin also exhibited an inverse effect on CatB
activity with respect to diminished proteasome function. Lactacystin caused earlier CatB
enhancement than Aβ42, and no correspondence was evident between up-regulated CatB
levels and the delayed synaptic pathology indicated by the loss of pre- and postsynaptic
markers. Contrasting the inverse effects on the proteasomal and lysosomal pathways by
Aβ42 and lactacystin, such were not found when CatB activity was up-regulated two-fold
with Z-Phe-Ala-diazomethylketone (PADK). Instead of an inverse decline, proteasome func-
tion was increased marginally in PADK-treated hippocampal slices. Unexpectedly, the pro-
teasomal augmentation was significantly pronounced in Aβ42-compromised slices, while
absent in lactacystin-treated tissue, resulting in >2-fold improvement for nearly complete
recovery of proteasome function by the CatB-enhancing compound. The PADK treatment
also reduced Aβ42-mediated tau phosphorylation and synaptic marker declines,
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corresponding with the positive modulation of both proteasome activity and the lysosomal
CatB enzyme. These findings indicate that proteasomal stress contributes to AD-type path-
ogenesis and that governing such pathology occurs through crosstalk between the two pro-
tein clearance pathways.
Introduction
Degradation of old and damaged proteins, through the proteasome and autophagy-lysosome
systems, decreases with age thus altering the vital balance between protein synthesis and
protein clearance (see reviews: [1–4]). This altered balance influences age-related neurodegen-
erative disorders, likely increasing the risk of protein accumulation disorders including Alzhei-
mer’s disease (AD) since deposition of amyloid and tau proteins develop long before the onset
of cognitive symptoms [5]. Altered levels of lysosomes, impaired maturation of autophagolyso-
somes, and other stress indicators of the autophagy-lysosomal pathway occur in AD brains [6–
8]. AD and mild cognitive impairment also exhibit compromised proteasome function as do
other age-related diseases [9–13]. Proteasomal dysfunction in the AD brain has been shown to
result from the inhibitory binding of filamentous tau to proteasomes [14], and a recent study
found that tau-driven proteasome impairment occurs in a mouse model of tauopathy [15]. In
addition, Aβ42 peptide oligomers inhibit proteasomes in vitro [16, 17], and 3xTg-AD mice
exhibit impaired proteasome activity correlating with intraneuronal oligomers [16]. The study
also found that proteasome inhibitors lead to increases in Aβ and tau levels in pre-pathological
3xTg-AD mice, thus pointing to proteasomal stress as a contributor to the multi-proteinopathy
of AD.
The proteasome and autophagy-lysosomal systems do not appear to be completely indepen-
dent protein clearance pathways [18–21], but rather exhibit evidence of concerted regulation
and crosstalk to maintain protein homeostasis. As an example of such crosstalk, autophagy
upregulation has been implicated as a response to compensate for proteasomal stress [17, 22–
24], with autophagy activation and lysosomal recruitment occurring in an HDAC6-dependent
manner. Also, proteasome inhibition has been shown to activate autophagy in order to elimi-
nate protein aggregates in human cancer cells and mouse fibroblasts [25], and such activation
of the lysosomal proteolytic pathway has been linked to chronic, low-level proteasome inhibi-
tion in neural SH-SY5Y cells [26]. Early activation of the autophagic-lysosomal pathway may
explain the abnormally high number of lysosomal compartments containing cathepsin B
(CatB) within neurons of at-risk regions from sporadic AD brains [27]. A positive modulator
of the autophagy-lysosomal system was recently found to enhance CatB activity and to reduce
Aβ42 accumulation in neuroblastoma cells expressing human amyloid precursor protein
(APP) with the Swedish mutation [28]. It is noteworthy that CatB regulation has been exten-
sively studied and the enzyme was found to be increased in response to the following types of
protein accumulation stress:
• chloroquine-induced protein accumulation stress in hippocampal slices [29]
• human huntingtin expression in cultured neurons [30]
• Aβ42 treatment of mouse neuronal cell line [31]
• expression of familial AD mutant APP in transgenic mouse brain [31]
• proteasome inhibitor treatment in rat hippocampus [32]
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• proteasome inhibitor treatment in control SH-SY5Y cells and those expressing human APP
[33]
The above CatB responses are of interest since such cellular responses may link the protea-
somal and lysosomal pathways during episodes of protein accumulation pathology. The
responses may in fact influence AD pathogenesis since CatB degrades Aβ42 through C-termi-
nal truncation [31, 34, 35], and such degradation was blocked by the selective CatB inhibitor
CA074 [31]. A similar inhibitor blocked the ability of a CatB-enhancing compound from
improving Aβ42 clearance in monocytes from AD patients [36]. In several transgenic mouse
models of AD, genetic and pharmacological treatments that increase CatB activity led to the
significant lowering of Aβ42 levels [31, 35, 37–41] as well as to reductions in the cellular and
behavioral disease parameters [31, 35, 37, 38, 41]. However, there is conflicting evidence about
the involvement of CatB in regards to protein accumulation events since reducing CatB has
also been shown to lower Aβ peptide levels and improve memory in transgenic mice [42, 43].
Due to the conflicting reports, it is important to further address the role CatB plays during pro-
tein accumulation pathology. Many questions obviously remain regarding the CatB enzyme
and the different roles proposed for it in the brain.
Protein clearance is vital for cellular homeostasis and the clearance rates for Aβ peptides
are indeed slower in AD as compared to cognitively normal individuals [44]. Accordingly, we
set out to understand how Aβ42 and a selective proteasome inhibitor influence the interplay
between the proteasomal and lysosomal protein clearance pathways in brain tissue. Using cul-
tured slices of a brain area that is vulnerable to AD, the present study will also examine CatB’s
response to proteasomal stress in order to understand its role in secondary pathogenic events.
Materials and methods
Hippocampal slice cultures
Sprague-Dawley rat litters (Charles River Laboratories, Wilmington, MA) were housed and
treated in accordance with the recommendations from the Guide for the Care and Use of Lab-
oratory Animals from the National Institutes of Health and in accordance with an approved
protocol from the Institutional Animal Care and Use Committee of the University of North
Carolina—Pembroke. Brain tissue from postnatal 12-day-old rats was rapidly removed to pre-
pare hippocampal slices [29, 45]. Transverse slices of hippocampus (400 μm) were quickly pre-
pared and the slices were kept in an iced buffer solution until groups of slices could be gently
positioned on the Biopore PTFE membrane of each Millicell-CM insert (Millipore, Billerica,
MA). Culture medium consisting of 50% basal medium Eagle, 25% Earle’s balanced salts, 25%
horse serum (Gemini Bio-products, Sacramento, CA), and defined supplements as described
[45] was changed periodically. The hippocampal slices were maintained at 37˚C in 5% CO2-
enriched atmosphere for 18–22 days before being treated with different agents. A subset of
slices were fixed and subjected to anti-synaptophysin immunocytochemistry, and images were
acquired using Zeiss 710 and Zeiss 780 confocal systems.
Treatments
Aβ42 peptide (American Peptide Company, Sunnyvale, CA) from precise aliquots was recon-
stituted in DMSO at 20 mM and diluted to 15 μM in phosphate-buffered saline. The diluted
peptide was allowed to aggregate in the dark at room temperature for 6 days before being uti-
lized for experiments in hippocampal slices cultures. Over a period of 4–6 days, pre-aggregated
Aβ42 diluted to 0.5–1.5 μM in serum-free media was applied to the cultured slices for 14–16 h.
Subsequently, horse serum-containing medium was mixed into culture wells, further diluting
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Aβ42 to 0.38–1.1 μM for 8–10 h before the next daily treatment. In other treatments, the irre-
versible proteasome inhibitor lactacystin (Santa Cruz Biotechnology, Santa Cruz, CA) was
applied daily to hippocampal slice cultures at 5–10 μM for 1–4 days. Other compounds and
lysosome-targeting agents (see ref. [46]) were also tested in the hippocampal slices to identify
CatB positive modulators. The compound Z-Phe-Ala-diazomethylketone (PADK, also known
as Z-FA-CHN2; Bachem, King of Prussia, PA) that promotes mature CatB levels in different
model systems [35, 47, 48] was diluted to 1–10 μM and applied daily to cultures in the absence
or presence of Aβ42. After the treatments, cultured slices were fixed in 4% paraformaldehyde
for histology or gently removed from the inserts into groups of 7–9 each using ice-cold isos-
motic buffer containing 0.32 M sucrose, 5 mM HEPES (pH 7.4), 1 mM EDTA and 1 mM
EGTA.
Immunoblot analysis
The groups of hippocampal slices were centrifuged and the pelleted tissue was sonicated in
cold lysis buffer consisting of 15 mM HEPES (pH 7.4), 0.5 mM EDTA, 0.5 mM EGTA, and a
protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO). Protein content was determined
using the Pierce BCA Protein Assay (Thermo Scientific, Rockford, IL). Equal protein aliquots
of the hippocampal slice samples were denatured in sample buffer for 5 min at 100˚C and the
proteins separated on gradient gels and transferred to nitrocellulose. Blots were incubated in
blocking solution containing 5% milk or BSA for 1 h. Primary antibody staining utilized anti-
bodies against synaptophysin (1:1000), synapsin II (1:500), cathepsin B (1:100), and GluR1
(1:500) from Millipore, as well as against actin (1:500) and phospho-tauSer199/202 (1:1000) from
Sigma-Aldrich and 20S proteasome α-1 subunit (1:500) from Santa Cruz Biotechnology. Anti-
IgG-alkaline phosphatase conjugates and anti-IgG-horseradish peroxidase conjugates were
used for the secondary antibody step, and antigen staining and image development involved
the 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium substrate system or
chemiluminescence protocols using Hyperfilm ECL exposures (GE Healthcare, Pittsburgh,
PA) as well as the GE Amersham AI600RGB imager. Immunostained bands were scanned at
high resolution to determine integrated optical density with BIOQUANT software (R & M
Biometrics, Nashville, TN).
Proteasome activity
The suc-LLVY-AMC substrate was used to assess the chymotrypsin-like proteasome activity
in hippocampal slice cultures. Samples of freshly harvested slice tissue were quickly homoge-
nized in assay buffer and equal protein aliquots (30 μg) in duplicate were incubated with a
fluorogenic substrate (Millipore) in 20 mM Tris buffer, pH 7.5, at 37˚C. The fluorescence
emission at 440 nm was measured periodically over a 45-min period using the SpectraMax M3
microplate reader. Lactacystin was added to a subset of control slice samples to determine that
>80% of the measured substrate cleavage was mediated by lactacystin-sensitive proteasome
activity.
Cathepsin B activity
The InnoZyme Cathepsin B Activity Assay Kit (Millipore) was used to measure CatB activity
in the hippocampal slice samples. Aliquots of homogenized samples (10 μg protein) were
assessed in duplicate for proteolytic activity using the Z-Arg-Arg AMC substrate and the
SpectraMax M3 microplate reader. The CatB specific inhibitor CA074 (10 μM) was added to a
subset of control slice samples to determine that all of the measured substrate cleavage was
mediated by CatB.
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Statistical analyses
For the results of mean and SEM values across treatment groups, statistical tests included lin-
ear regression analysis, unpaired t tests, and analyses of variance (ANOVA) followed by post
hoc tests using Prism software (GraphPad, San Diego, CA).
Results
To test for changes in the proteasome pathway that are related to the AD Aβ42 peptide, the
peptide’s effects were assessed in stable explants of brain tissue. Rat hippocampal slice cultures
were used, a method providing mature brain tissue that maintains native neuronal organiza-
tion and synaptic density (Fig 1a and 1b) as well as other features of the adult hippocampus
[49]. Aβ42 was first allowed to self-aggregate for 6 days following a previously established pro-
tocol [50] in order to evaluate oligomeric species thought to be involved in AD-related stress
on cellular homeostasis. Hippocampal slice cultures were treated daily with the pre-aggregated,
low-concentration Aβ42 and as a result proteasome chymotrypsin-like activity was reduced by
more than 60% after 4–6 days (Fig 1c). Note that the proteasome assay measured activity that
is sensitive to 20S proteasome inhibitors, but the loss of proteasome function due to Aβ42
occurred in the absence of any change in the 20S proteasome α-1 subunit (Fig 1d).
The compromised proteasome activity was tested for a link to secondary synaptic pathology
since the proteasome pathway has a major role in regulating synaptic proteins [51]. The Aβ42-
induced proteasome inhibition was indeed associated with a significant loss in synaptophysin
(Fig 1e). The presynaptic marker was reduced by 61% as compared to control hippocampal
slice cultures, whereas other proteins including actin were unchanged. Note that the reduc-
tions in synaptophysin and proteasome activity were similar in degree and they occurred in
correspondence with an Aβ42-mediated increase in tau species, isoforms identified as being
phosphorylated on Ser199 and Ser202 (Fig 2). Thus, the effects of proteasome dysfunction in
the brain may involve a previously identified pathogenic cascade linking tau deposition and
gradual synaptic decline [45]. The 55- to 70-kDa phospho-tau immunoreactivity, normalized
to within-sample actin levels, was increased two-fold after hippocampal slices were treated for
6 days with 0.5–1.5 μM pre-aggregated Aβ42 (p<0.0001).
Next, we tested whether the Aβ42-mediated proteasome compromise leads to changes in
the lysosomal pathway since Aβ42 preparations [29, 31, 52] and proteasome inhibitors [32, 33]
have been shown to increase lysosomal cathepsin enzymes. In hippocampal slice cultures, pro-
teasome activity was significantly decreased 62% by a preparation of pre-aggregated Aβ42 over
a 6-day treatment period (Fig 3a). Note after 4 days of Aβ42 treatment, the reduction in protea-
some function was not associated with any activity change regarding the lysosomal enzyme
CatB. However, it is of interest that after 6 days of treatment the CatB activity exhibited a strik-
ing 2–3-fold increase over the baseline level (p = 0.0025). The delayed up-regulation in CatB
activity shown in Fig 3a does not correspond with Aβ42-mediated increases in pTau-Ser
199/202
species (Fig 3b) since the latter occurred prior to the CatB response.
To test if CatB responds to another type of proteasomal stress, cultured hippocampal slices
were treated with the 20S proteasome inhibitor lactacystin. As with Aβ42 treatment, lactacystin
significantly reduced proteasome activity (Fig 4a) but it had a larger inhibitory effect than that
produced by the pre-aggregated Aβ42. The dashed line in Fig 4a represents control proteasome
activity, and Fig 5 confirms that mature hippocampal slice cultures stably maintain proteaso-
mal activity across several weeks in culture. The lactacystin-induced decline in proteasome
function was also found to be independent of any change in the 20S proteasome α-1 subunit
(Fig 4b) as was found with Aβ42. Comparing lactacystin with Aβ42 with regards to CatB modu-
lation, lactacystin had an inverse effect on CatB activity, as did Aβ42, with respect to the
Aβ42-induced proteasome stress and tau pathology are governed by a compensatory lysosomal response
PLOS ONE | https://doi.org/10.1371/journal.pone.0182895 August 10, 2017 5 / 26
Fig 1. Pre-aggregated Aβ42 causes proteasomal dysfunction in correspondence with synaptic decline in rat hippocampal slice
cultures. The brain tissue was maintained on culture inserts with media placed below the insert membrane—note the two Nissl-stained
slices showing their insert positions and neuronal layers (a) (size bar = 3 mm). After several weeks in culture, a hippocampal slice was
stained with anti-synaptophysin and DAPI to show the stable maintenance of CA1, CA3, and dentate gyrus subfields and their associated
dense neuropil (b) (view-field width: 2.6 mm). Aliquots of pre-aggregated, human Aβ42 peptide were diluted to 0.5–1.5 μM and applied daily
to slice cultures alongside vehicle-treated slices. Proteasome chymotrypsin-like activity (mean Vmax/s ± SEM normalized to control; n = 6)
was measured in hippocampal slices that were harvested after 4–6 days of treatment (c). For immunoblots, groups of 7–9 slices each were
harvested after 6 days of treatment, sonicated, and equal protein aliquots assessed for the 20S proteasome α-1 subunit (d), synaptophysin
(SNP; e), and actin. Mean immunoreactivity levels were normalized to their respective controls and percent ± SEM values are shown.
Unpaired t-tests: ***p< 0.001.
https://doi.org/10.1371/journal.pone.0182895.g001
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Fig 2. Treatment with pre-aggregated Aβ42 peptide leads to increased phosphorylation of tau
residues Ser199 and Ser202. Hippocampal slice cultures were treated daily with Aβ42 alongside vehicle-
treated slices. After 6 days the tissue was gently harvested into groups of 7–9 slices each and equal protein
aliquots assessed by immunoblot with antibodies against phospho-tau-Ser199/202 and against actin (a).
Positions of molecular weight standards are shown. The 55–70-kDa phospho-tau immunoreactivity levels
were normalized to within-sample actin measures and plotted as mean percent of control ± SEM (b). Unpaired
t-test: ***p< 0.001.
https://doi.org/10.1371/journal.pone.0182895.g002
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Fig 3. Aβ42-induced proteasome inhibition is associated with a delayed, inverse effect on CatB
activity. Hippocampal slice cultures were treated daily with vehicle for 6 days (0-day control group) or with
pre-aggregated Aβ42 for 4–6 days, staggering the treatments in order for same-day harvesting of slice groups
of 7–9 each. Proteasome activity (gray plot of mean Vmax/s ± SEM; ANOVA: p<0.01) and cathepsin B activity
(black plot of mean fluorometric units ± SEM; ANOVA: p<0.01) were measured in equal protein aliquots from
the same samples (a). The time-course samples were also assessed for 55–70-kDa pTau-Ser199/202 and actin
in order to plot the within-sample ratios between the immunoreactivity levels (b; mean ± SEM). Tukey post hoc
tests compared to vehicle-treated slices: **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0182895.g003
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Fig 4. Proteasome activity is blocked by the inhibitor lactacystin in hippocampal slice cultures. The
slices were treated daily with vehicle for 4 days (0-day control group) or with 5 μM lactacystin for 1–4 days,
staggering the treatments in order for same-day preparation of slice groups of 7–9 each. Proteasome activity
(mean Vmax/s ± SEM) was measured in control slices harvested at different times (dashed line) and in
lactacystin-treated slice samples (a). The time-course data were analyzed by ANOVA (p<0.0001; post hoc
tests compared to control: p<0.0001 at all 4 time points). A subset of the samples tested for proteasome
Aβ42-induced proteasome stress and tau pathology are governed by a compensatory lysosomal response
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inhibitory action on the proteasome pathway (Table 1). A difference was apparent in that lac-
tacystin elicited earlier CatB up-regulation compared to Aβ42’s effect that was delayed more
than 4 days. A 28% increase in CatB activity was found after only the first day of lactacystin
treatment (nearing significance with p = 0.054), and subsequent treatment days resulted in
markedly up-regulated activity, increasing by 62–109% in a time-dependent manner
(p<0.001). Note that the increase in CatB activity by lactacystin was not associated with any
change in the 30-kDa active isoform of the CatB enzyme (see Fig 4c). The 30-kDa isoform in
slice samples with 2–4 days of treatment was 117 ± 20.3% of control (n = 7; N.S.).
The CatB response induced by lactacystin does not appear to correspond with the develop-
ment of secondary pathology, in this case the delayed loss of synaptic proteins. Enhancement
of CatB activity was occurring after 1–2 days of lactacystin treatment (Table 1), whereas the
loss of synaptophysin and synapsin IIb in particular did not become evident until slices were
treated for 3–4 days (Fig 6a). In the same lactacystin-treated samples tested for proteasome
and CatB activities, 46–60% reductions at latter time points were evident by immunoblot stain-
ing for synaptophysin (p = 0.0015), GluR1 (p<0.01), and synapsin IIb (p<0.01), while no
change in synapsin IIa was found (see Fig 6a and 6b). The loss of synapsin IIb is a distinct
activity was also assessed by immunoblot for the 20S proteasome α-1 subunit (20S) and actin (b), as well as
for GluR1, synaptophysin (SNP), the 30-kDa CatB isoform (CatB-30), and again the actin load control (c).
https://doi.org/10.1371/journal.pone.0182895.g004
Fig 5. Hippocampal slice cultures exhibit stable proteasomal activity. Proteasome activity was measured with a fluorogenic
peptide assay in control hippocampal slices harvested across a wide range of culture days. The mean Vmax/s ± SEM data were
plotted across days in culture for the different slice samples in order to verify stable maintenance of proteasome function in the tissue model.
https://doi.org/10.1371/journal.pone.0182895.g005
Aβ42-induced proteasome stress and tau pathology are governed by a compensatory lysosomal response
PLOS ONE | https://doi.org/10.1371/journal.pone.0182895 August 10, 2017 10 / 26
indicator of synaptic decline induced by lactacystin since Aβ42 had little to no effect on synap-
sin II isoforms (data not shown) as previously reported [50]. This more extensive effect on syn-
aptic integrity may be due to lactacystin causing more proteasomal inhibition than Aβ42,
noting that the residual proteasome activity (~50%) after 4 days of Aβ42 treatment was blocked
to the level of 98.5% inhibition when lactacystin was included during the Aβ42 incubation.
Also distinctive to lactacystin was the strong relationship between levels of the two susceptible
markers, synapsin IIb and synaptophysin (Fig 6c; correlation coefficient of 0.913) across a set
of treatment samples, whereas no relationship was evident between synapsin IIa and synapto-
physin (Fig 6d).
Since proteasomal inhibition by two different stressors, Aβ42 and lactacystin, led to increased
CatB activity, we next tested whether enhancing CatB leads to reduced proteasome activity to
follow the inverse relationships identified in the above experiments. From the screening of
compounds that target CatB and related proteases (Table 2), those with very weak abilities to
inhibit CatB curiously exhibited the ability to up-regulate levels of the 30-kDa active CatB iso-
form in hippocampal slices. Of note, modest dose-dependent increases were found with E64d
(ANOVA: p<0.0001) and Cathepsin Inhibitor 1 (p = 0.0018). Z-Phe-Ala-diazomethylketone
(PADK) at 1–10 μM caused a 3- to 6-fold selective increase in CatB-30 (ANOVA: p<0.0001)
compared to unchanged synaptic markers (see Fig 7a) and the actin load control (not shown),
as also previously reported for CatB activity in in vitro and in vivo studies [35, 47]. Thus PADK
was chosen as a very effective CatB-enhancing agent to be used to test for inverse effects on the
protein clearance pathways. When a set of hippocampal slice cultures were treated with 3 μM
PADK and subsequently washed and assessed for both proteasomal and CatB proteolytic activi-
ties, a significant two-fold increase in CatB activity was found (Fig 7b, left bars) which was
blocked if the PADK incubation included the potent CA074 inhibitor of CatB (not shown).
With regards to proteasomal function, rather than a decrease for an inverse effect with respect
to the CatB modulation, PADK elicited a 15% increase in proteasome activity, albeit not quite
statistically significant (Fig 7b, right bars).
In contrast to the inverse effects that Aβ42 and lactacystin produced on the proteasomal and
lysosomal pathways, the CatB positive modulator PADK did not produce such results since it
clearly did not have a negative effect on proteasome function (Fig 7c). Surprisingly, PADK’s
small enhancing effect on proteasome activity was much more pronounced in hippocampal
slices that were treated for 6 days with Aβ42 peptide. The Aβ42–compromised proteasome
activity (65% reduction) was improved more than two-fold by the co-application of PADK
Table 1. Lactacystin-induced proteasome inhibition leads to the enhancement of CatB activity.
Treatment days CatB activity, percent ± SEM
vehicle 4 100 ± 10.7
lactacystin 1 128 ± 8.7
lactacystin 2 162 ± 10.2*
lactacystin 3 209 ± 20.2***
lactacystin 4 204 ± 4.6***
Hippocampal slice cultures were treated daily with vehicle for 4 days or with 5 μM lactacystin for 1–4 days,
staggering the treatments in order for same-day preparation of slice groups of 7–9 each. CatB activity was
measured in equal protein aliquots of samples and fluorometric units were normalized to vehicle-treated
control samples. Tukey post hoc tests compared to vehicle treatment:
*p = 0.028.
***p<0.001.
https://doi.org/10.1371/journal.pone.0182895.t001
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during the entire 6- day protocol (Fig 8a), reaching levels comparable to those in control slice
cultures. From the statistical test, pre-aggregated Aβ42 was unable to produce a significant
decline in proteasomal function in the presence of 3 μM PADK. It was also determined that
PADK uniquely modulates the proteasome protein clearance pathway in Aβ42–treated brain
Fig 6. The proteasome inhibitor lactacystin causes delayed synaptic marker loss in hippocampal
slice cultures. The hippocampal slices were treated daily with vehicle for 4 days (0-day control group) or with
5 μM lactacystin for 1–4 days, and treatments were staggered for same-day harvesting of 7–9 slices per
group. The samples were assessed by immunoblot (a), staining the proteins synaptophysin (SNP), synapsin
IIa (syn IIa) and IIb (syn IIb), GluR1, and actin. Mean synapsin levels were normalized to their respective
controls and percent ± SEM values are shown for the time points with distinct effects between the two
isoforms (b). Across the set of immunoblot samples, the levels of synaptophysin were plotted against the
within-sample measures of synapsin IIb (c) and synapsin IIa (d). Linear regression analysis was conducted (c:
R = 0.913, p<0.001; d: R = -0.430, N.S.).
https://doi.org/10.1371/journal.pone.0182895.g006
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tissue since the lactacystin-treated slices, those exhibiting more proteasomal inhibition than
that produced by Aβ42, were unaffected by PADK with regards to recovery of proteasome
function (Fig 8b).
Since pre-aggregated Aβ42 caused a delayed increase in CatB activity with no evidence of
recovery regarding proteasome activity (see Fig 3a), we tested whether PADK can improve
proteasome function when applied in a delayed manner, being administered after the first 3
days of the 6-day Aβ42 treatment protocol. As with continuous exposure, the delayed applica-
tion of 3 μM PADK was still able to attenuate the Aβ42–induced decline in proteasome activity
(Fig 9a). In association with the nearly two-fold improvement in proteasomal function, the
active CatB-30 isoform was also up-regulated when daily inclusion of PADK was delayed 3
days (Fig 9b). Of particular note, the 6-day Aβ42 treatment alone did not affect CatB-30 levels.
Thus, the up-regulation of CatB activity by both Aβ42 and lactacystin occurs independent of
altered CatB-30 levels, indicating a distinct mechanistic difference compared to PADK’s robust
increase in the active CatB isoform in association with activity modulation.
In the Aβ42–treated hippocampal slice cultures, the PADK compound had a positive influ-
ence on both the proteasome system and the CatB enzyme of the autophagic-lysosomal system.
Accordingly, the experimental samples were also tested for PADK effects on the indications of
Aβ42–induced secondary pathology in the slice model. As shown in Fig 10a, PADK reduced
Table 2. Among screened compounds, PADK was chosen as an effective CatB-enhancing agent for
further testing in the hippocampal slice model.
compound CatB-30, percent ± SEM (n) IC50 for CatB, μM
vehicle control 100.0 ± 4.0 (11) –
PADK 1 μM 340.0 ± 38.7 (4)** 9–11 (from ref. [35])
3 μM 462.1 ± 95.8 (6)***
10 μM 649.1 ± 74.5 (9)***
SD1002 10 μM 345.0 ± 13.3 (4)** >50 (from ref. [39])
E64d 1 μM 115.0 ± 9.2 (4) 14 (from ref. [53])
3 μM 122.2 ± 17.7 (3)
10 μM 176.1 ± 12.5 (6)***
E64 0.03–0.05 μM 144.0 ± 12.3 (4)* 0.03 (from ref. [54])
1–2 μM 111.5 ± 7.5 (4)
Cathepsin Inhibitor-1 0.3–1 μM 120.9 ± 16.4 (3) weak inhibitor (from ref. [55])
10 μM 149.4 ± 14.3 (3)**
CA074 0.05 μM 89.0 ± 15.9 (3) 0.004 (from refs. [53, 54])
0.3–1 μM 95.3 ± 11.9 (3)
CA074me 0.3–1 μM 116.0 ± 9.2 (6) 0.12 (from ref. [35])
lactacystin 5 μM 117.0 ± 20.3 (7) >100 (from ref. [56])
The slice cultures were treated daily with vehicle or with the noted concentrations of selected compounds for
2–3 days. Tissue was then collected into slice groups of 7–9 each for immunoblot analysis. Detection of the
30-kDa CatB isoform (CatB-30) was measured in equal protein aliquots of samples and normalized to
vehicle-treated control samples. Unpaired t test compared to vehicle treatment:
*p<0.05.
ANOVA multiple comparison tests compared to vehicle control:
**p<0.01.
***p<0.001.
A wide range of IC50 values for inhibiting CatB activity is provided for the ineffective to very effective
compounds, obtained from the listed references.
https://doi.org/10.1371/journal.pone.0182895.t002
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Fig 7. The effective CatB-enhancing agent PADK (chosen from Table 2) selectively enhances CatB
activity in hippocampal slice cultures. The slice cultures were treated daily with vehicle or 3 μM PADK for 2
days before being collected into slice groups of 7–9 each. Panel a: Immunoblot assessments stained the 30-
and 25-kDa CatB isoform (CatB-30 and CatB-25), GluR1, and synaptophysin (SNP). Panel b: Fluorogenic
peptide assays assessed the harvested slice samples for cathepsin B and proteasome chymotrypsin-like
activities. The two measures were normalized to their respective vehicle control groups (mean ± SEM).
Cathepsin B activity exhibited a significant increase, whereas proteasome activity exhibited only a small
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tau phosphorylation mediated by the low-concentration Aβ42 incubations, perhaps due to
multiple influences on protein clearance pathways. The hippocampal slices treated with pre-
aggregated Aβ42 exhibited a two-fold increase in levels of phospho-tau-Ser
199/202 and these lev-
els were reduced by nearly 50% when PADK was present during the 6-day Aβ42 treatment
period (Fig 10b). Additionally, the decrease in phospho-tau species corresponds with PADK’s
enhancement of the active CatB isoform and improved levels of synaptic markers (Fig 10c).
Hence, enhancement of the crosstalk that occurs in response to proteasomal stress appears to
govern secondary events linked to Aβ42 pathology (see Fig 11).
Discussion
In this study, low-level Aβ42 reduced proteasome activity in slice cultures from the hippocam-
pus, a brain region vulnerable to AD, and the proteasomal compromise was associated with
increased levels of phosphorylated tau species. These results indicate that AD-related protea-
some dysfunction may be due to alterations in regulatory factors of the ubiquitin-proteasome
system, leading to protein accumulation stress and perhaps neurofibrillary pathology. The
important proteasome pathway has previously been shown to efficiently degrade misfolded
and ubiquitinated proteins [57], and functional impairment of proteasomes impacts aging and
age-related neurodegenerative diseases [1, 14, 13]. From the current results, proteasome dys-
function appears to tie together two key components of AD multi-proteinopathy, the Aβ42
peptide and tau, while leading to synaptic marker reductions in the slice model. The Aβ42 pep-
tide was self-aggregated before being applied to the cultured brain tissue in order to resemble
the oligomeric species present in AD brains. Note that Aβ42 oligomers, but not the monomeric
form, were found to cause significant inhibition in a cell-free proteasome assay [16]. In the
hippocampal slice model, the proteasomal protein clearance pathway is distinctly vulnerable to
Aβ42 as compared to a lysosomal enzyme (CatB) that was not disrupted by the oligomerized
peptide. Similar to Aβ42 treatment, disrupting the proteasomal pathway with the inhibitor lac-
tacystin also led to secondary pathology in the hippocampal slices as indicated by the loss of
synaptic proteins. Also common between Aβ42 and lactacystin, they both triggered a distinct
type of lysosomal response involving the CatB enzyme.
The importance of protein clearance systems in AD is noted by the fact that Aβ peptides
exhibit decreased clearing rates in the disease [44]. As suggested by the present results, early
Aβ42 oligomerization may gradually disrupt proteasome function and thereby lead to reduced
clearance of APP fragments, Aβ peptides, tau species, and perhaps other proteins involved in
AD-related protein accumulation pathology. Aβ42-induced synaptic decline in the slice cul-
tures may be partly an indirect effect mediated by proteasome inhibition since both Aβ42 and
lactacystin caused significant reductions in synaptic proteins. Such loss of synaptic markers by
low-concentration Aβ42 was found previously with regards to pre- and postsynaptic constitu-
ents found reduced in AD [50]. Additionally, lactacystin has been shown to induce another
type of protein accumulation pathology in which the proteasome inhibitor was administered
intranigrally for a mouse model of Parkinson’s disease [58]. The evidence linking a compro-
mised proteasome system with synaptic pathology adds to studies showing that proteolysis
through proteasomes is important for synaptic mechanisms and plasticity processes [51]. A
series of steps may underlie the synaptopathogenesis [45], perhaps initiated by cellular inter-
nalization of the applied Aβ42 [59], the intraneuronal oligomers subsequently inducing tau
increase. Panel c: Percent changes in CatB (white) and proteasome (black) activities compared to control are
shown for 6-day Aβ42 treatment (from Fig 3a data), for 4-day lactacystin treatment (from Fig 4a and Table 1
data), and for 2-day PADK treatment (from Fig 7b data).
https://doi.org/10.1371/journal.pone.0182895.g007
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Fig 8. The CatB-enhancing compound PADK positively modulates the proteasome pathway in Aβ42–
treated hippocampal slice cultures. Panel a: Slice cultures were treated daily with vehicle (veh) or 1.5 μM
pre-aggregated Aβ42 for 6 days, or they were pre-treated with 3 μM PADK for 1 day before starting the 6 daily
Aβ42 treatments in combination with 3 μM PADK. Proteasome activity was measured with a fluorogenic
peptide assay and Vmax/s measures were normalized to vehicle-treated samples (mean ± SEM). Unpaired t
test compared to control: *p = 0.0196; compared to Aβ42 alone: ##p = 0.027. Panel b: Slice cultures were
treated with vehicle (veh), 10 μM lactacystin (LAC), or with 10 μM LAC in the presence of PADK for 2 days.
Proteasome activity was assessed in harvested slices and measures were normalized to vehicle-treated
samples (mean ± SEM). Unpaired t test compared to vehicle control: ***p<0.0001.
https://doi.org/10.1371/journal.pone.0182895.g008
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Fig 9. Aβ42–induced decline in proteasome activity is diminished by delayed PADK treatment. Panel a:
Hippocampal slice cultures were treated daily with vehicle (veh) or 1.5 μM Aβ42 for 6 days, or they were
subjected to the 6 daily Aβ42 treatments but 3 μM PADK was included during the last 3 days of Aβ42
incubations. Proteasomal activity used a fluorogenic peptide assay in harvested slice samples and Vmax/s
measures were normalized to vehicle-treated control samples (mean ± SEM). Panel b: The harvested
samples were also assessed by immunoblot for the 30-kDa active CatB isoform (CatB-30) and the actin load
control. Mean CatB-30 levels were normalized to control values and percent ± SEM values are shown.
Unpaired t tests compared to Aβ42 alone: #p<0.05.
https://doi.org/10.1371/journal.pone.0182895.g009
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Fig 10. Aβ42–induced increase in phosphorylated tau is attenuated by PADK. Hippocampal slice
cultures were treated daily with vehicle for 6 days (0-day control) or with 1.5 μM pre-aggregated Aβ42 for 4–6
days in the absence of presence of 3 μM PADK. The treatment schedule was staggered in order for same-day
harvesting of 7–9 slices per group. Equal protein aliquots of the slice samples were assessed by immunoblot
with antibodies against phospho-tau-Ser199/202 and against actin (a). Positions of molecular weight standards
of 49–76 kDa are shown on the right. Integrated optical densities were measured and within-sample ratios
between the two antigens were plotted for the 6-day treatments (b); note that the ratios were normalized to
vehicle-treated samples (mean ± SEM). Unpaired t tests compared to vehicle control: **p<0.01; compared to
Aβ42-induced proteasome stress and tau pathology are governed by a compensatory lysosomal response
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Aβ42 alone: #p<0.05. Additional immunblot samples were stained for phospho-tau-Ser199/202, the 30-kDa
CatB isoform (CatB-30), synaptophysin (SNP), GluR1, and actin (c).
https://doi.org/10.1371/journal.pone.0182895.g010
Fig 11. Model of the putative crosstalk between the two major protein clearance pathways. The autophagic-lysosomal
system consists of autophagosomes, endosomes, primary lysosomes, and secondary lysosomes. The proteasomal system
is composed of multimeric complexes with a catalytic core and regulatory subunits. Oligomerized Aβ42 and lactacystin elicit
proteasomal inhibition which is linked to positive crosstalk with a component of the lysosomal pathway. Enhancing such
compensatory lysosomal responses with a CatB-enhancing agent also leads to positive crosstalk back to the proteasome
system.
https://doi.org/10.1371/journal.pone.0182895.g011
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pathology [60, 61], and altered tau species then interfering with proteasome function [14, 15].
It is feasible that the different protein accumulation events act synergistically on a variety of
cellular mechanisms to disrupt synaptic integrity (e.g., through microtubule destabilization,
impaired cellular transport, axonopathy, and/or ion channel deregulation).
Interestingly, the negative effect Aβ42 had on proteasomes was associated with a delayed
enhancement of the lysosomal system in the form of an increase in CatB activity 6 days after
initiating the Aβ42 treatment. When assessing the two protein clearance pathways after 4 days
with Aβ42, the proteasome pathway appears to be selectively targeted since no change in CatB
activity was evident in the slice cultures. The proteasome inhibition produced after 4–6 days of
Aβ42 incubations was associated with synaptic marker loss and increased levels of phospho-
tau. Noting that the up-regulation of CatB activity did not correspond with the initial elevation
of pTau-Ser199/202 species, perhaps the delayed CatB response is only triggered by the subse-
quent higher levels of phospho-tau or by some interaction between the applied Aβ42 oligomers
and the induced tau deposition that requires extra time to manifest. Note that human neuro-
blastoma cells treated with Aβ42 also exhibited proteasome inhibition and deregulation of the
autophagic-lysosomal pathway, the latter confirmed by increased cathepsin activity [17]. In
addition, treatment with Aβ42 but not Aβ40 was shown to increase both CatB mRNA and
enzyme activity in the mouse N2A neuronal cell line [31]. Aβ42 levels 10–20 times higher than
what was used here were found to elicit earlier cathepsin responses in slice and neuronal cul-
tures [29, 31]. Thus, Aβ42 at a concentration more relevant to human AD points to proteaso-
mal compromise as being associated with a delayed lysosomal response.
A positive CatB response was evident when proteasomes were disrupted by either Aβ42 or
lactacystin in hippocampal slices, thus furthering the idea that the proteasomal and lysosomal
systems are not independent protein clearance pathways. In both cases, the proteasomal dys-
function resulted in enhanced levels of lysosomal CatB activity. As previously noted, the two
pathways appear to interact and the resulting crosstalk between proteasomes and the autop-
hagy-lysosomal system may work to maintain protein homeostasis [12, 19, 21, 32]. The up-reg-
ulated CatB activity, induced by either Aβ42 or lactacystin, did not appear to correspond with
secondary events of phospho-tau accumulation or synaptic marker reductions. Moreover,
when CatB was enhanced with a selective modulator, no evidence of synaptic decline occurred
when the compound was applied to hippocampal cultures alone, and it elicited protection of
proteasome function and reduction in secondary pathology in the Aβ42–treated slice cultures.
Note that the delayed CatB enhancement induced after 6 days of Aβ42 exposure may have in
fact slowed the rate of tau changes since no further increase in phospho-tau levels was evident
between 4 and 6 days of Aβ42 treatment. The PADK CatB-enhancing compound was more
protective with regards to the tau alterations, perhaps due to its unique ability to greatly
increase levels of the active CatB isoform. The modulation of CatB activity stemming from
Aβ42– and lactacystin—induced proteasomal stress transpires independent of any evident
changes in the CatB-30 isoform. The noted modulation events are indicative of positive cross-
talk between the major protein clearance systems, as depicted in Fig 11, to potentially reduce
protein accumulation stress and attenuate the pathogenic cascade that leads to synaptic dys-
function [45, 62]. Compensatory activation of a lysosomal enzyme may be in response to Aβ42
itself or through positive crosstalk stemming from the Aβ42–induced proteasomal stress.
Different types of protein accumulation stress have been shown to increase CatB levels in
research models [29, 31]. Many questions obviously remain regarding CatB, particularly since
the protease has been suggested to be a biomarker of AD as higher CatB protein levels were
found in serum and plasma samples from persons with AD [63, 64]. However, recent work
with human AD hippocampal samples did not show a correlation between CatB and the
degree of AD pathology [65]. In their study, laser-captured CA1 pyramidal neurons from cases
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assigned a Braak stage III diagnosis exhibited a 35% increase in CatB protein as compared to
nondemented control groups, whereas a smaller, insignificant change in CatB was found in
neurons from the more severe Braak stage V. Thus, the reported higher CatB levels in AD may
be an indication of a compensatory lysosomal response, and perhaps the weaker response in
more severe cases explains an increased vulnerability that leads to worsening cognition and
higher Braak rating. Note that compensatory responses are likely vital to maintain protein
homeostasis and may act to slow protein accumulation pathology, perhaps explaining the slow
nature of AD that tends to gradually worsen over 5–20 years in some individuals. In fact, indi-
cators of protein accumulation stress in the AD brain include the induction of the autophagy-
lysosomal pathway as well as impairment in lysosomal maturation [6, 7]. Also considering the
compensatory lysosomal response, any depletion in such responses by a protein clearance
pathway would lead to increased vulnerability to pathogenic protein accumulation. Two
reports indicate that compensatory responses by lysosomes are diminished or absent in aged
animals. In hAPP mice with amyloidogenic events, CatB activity was increased in the hippo-
campus of young and middle-aged animals, but not in the elderly hAPP mice [31]. In a rat
model of proteasome stress, compensatory crosstalk between the proteasome system and the
autophagy-lysosome pathway was found in young but not aged rats, and restoration of protein
homeostasis occurred only in hippocampal neurons of the young animals [32]. Thus, age-
related changes in lysosomal compensatory responses may explain why age is a major risk fac-
tor of AD.
In regards to plasma CatB levels leading some to speculate a link to AD cognitive pathology,
a more recent study found the opposite in monkeys and humans in which treadmill exercise
elevated CatB in plasma and, moreover, the resulting CatB enhancement correlated with
improved hippocampal-dependent memory [66]. These findings are consistent with animal
models and human research indicating that physical activity can significantly offset the pro-
gressive loss of hippocampal function and prevent or delay the onset of age-related disorders
like AD and AD-related dementias [67].
The CatB-enhancing PADK compound is a very weak cathepsin B and L inhibitor that aug-
ments the active mature form of CatB when applied to the hippocampal cultures alone. In
regards to protein accumulation stress in the slice model, the PADK treatment reduced the
Aβ42–mediated phospho-tau accumulation and associated synaptic decline. If the CatB up-reg-
ulation in response to Aβ42–induced proteasomal stress is part of a compensatory feedback
pathway, then it stands to reason that a compound that promotes the compensating signal
would further protect against secondary pathology linked to the disrupted proteasomes. It is
noteworthy that other weak cathepsin inhibitors were also found to up-regulate active CatB
including i) SD1002, a nonpeptidic PADK analogue previously shown to promote Aβ42 clear-
ance and synaptic integrity in AD mice [39], ii) Cathepsin Inhibitor-1, a broad inhibitor of
papain and cathepsins B, G, L, and S, and iii) E64d, a membrane-permeable inhibitor of several
cysteine proteases that has been reported to inhibit CatB to reduce Aβ and improve memory
in APP mice [42]. However, studies also indicate that the latter compound blocks both the cal-
cium-activated protease calpain and CatB to protect against other neuropathogenic insults [53,
68] and can elicit neuroprotection through a CatB-independent pathway [69]. The positive
response through CatB may be an influential factor in AD pathogenesis, allowing the lyso-
somal system to play an important role in governing Aβ pathology. While there is conflicting
evidence regarding CatB in the development of AD, it should be pointed out that i) CatB was
found to cleave Aβ42 into less amyloidogenic species [31], ii) the C-terminally truncated prod-
ucts Aβ38 and Aβ33 appear to be selectively cleaved from Aβ peptides by purified CatB [31, 34],
and iii) production of the Aβ38 product corresponds with improved Aβ42 clearance in trans-
genic mice treated with the CatB-enhancing compound PADK [35]. Aβ peptides were also
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reduced by genetic and pharmacological avenues that increase CatB activity in mice expressing
hAPP with AD-linked mutations [31, 35, 37–39, 41, 48] or wild-type hAPP [40], as well as in
neural progenitor cell-derived neurons expressing mutant hAPP [41]. As mentioned, induc-
tion of the autophagy-lysosomal pathway has long been suggested as being neuroprotective
against protein accumulation disorders. The very weak inhibitors appear to promote CatB
maturation and may provide dual modulation of the separate systems for clearance of patho-
genic proteins.
The results in this study suggest that AD-related proteasomal stress contributes to distinct
protein accumulation pathology. Age-related protein accumulation events may create circum-
stances that strain the proteasomal system, leaving the brain more vulnerable to AD-type path-
ogenesis. If proteasome function is in fact vulnerable to the early buildup of Aβ42 in AD,
protective modulation of the proteasomal system would be a viable treatment strategy. It is of
interest that the lysosomal system responds to proteasome inhibition and that a CatB-enhanc-
ing agent elicits recovery of proteasomal function. Note that the autophagy-lysosomal system
has long been considered a major factor for neuronal health and that induction of this lyso-
some-mediated degradative pathway is often found to be protective in animal models of
neurodegenerative diseases [18, 19, 22, 24, 70]. The current findings further support the idea
that interactions occur between the proteasome system and the lysosomal protein clearance
system during episodes of protein accumulation stress. Together, the two pathways make up a
complimentary network for cell homeostasis, and modulated balancing between the two path-
ways through compensatory responses is a likely cellular attribute for maintaining consistent
clearing of old and mis-folded proteins.
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